References: Antipsychotic regimens for a first episode of psychosis in adults and young people

  • Agid O, Schulze L, Arenovich T, Sajeev G, McDonald K, Foussias G, et al. Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching. Eur Neuropsychopharmacol 2013;23(9):1017–22. https://www.ncbi.nlm.nih.gov/pubmed/23706529
  • Early Psychosis Guidelines Writing Group; EPPIC National Support Program. Australian clinical guidelines for early psychosis. 2nd update ed. Melbourne: Orygen, the National Centre of Excellence in Youth Mental Health; 2016. https://www.orygen.org.au/Training/Resources/Psychosis/Clinical-practice-points/Australian-Clinical-Guidelines-for-Early-Psychosis
  • Emsley R, Rabinowitz J, Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry 2006;163(4):743–5. https://www.ncbi.nlm.nih.gov/pubmed/16585455
  • Findling RL, Cavus I, Pappadopulos E, Vanderburg DG, Schwartz JH, Gundapaneni BK, et al. Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study. J Child Adolesc Psychopharmacol 2013;23(8):531–44. https://www.ncbi.nlm.nih.gov/pubmed/24111983
  • Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry 2016;50(5):410–72. https://www.ncbi.nlm.nih.gov/pubmed/27106681
  • Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012;13(5):318–78. https://www.ncbi.nlm.nih.gov/pubmed/22834451
  • Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Chaimani A, et al. Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis. Eur Neuropsychopharmacol 2018;28(6):659–74. https://www.ncbi.nlm.nih.gov/pubmed/29802039
  • Shimomura Y, Kikuchi Y, Suzuki T, Uchida H, Mimura M, Takeuchi H. Antipsychotic treatment in the maintenance phase of schizophrenia: An updated systematic review of the guidelines and algorithms. Schizophr Res 2020;215:8–16. https://www.ncbi.nlm.nih.gov/pubmed/31784340
  • Weber J, McCormack PL. Asenapine. CNS Drugs 2009;23(9):781–92. https://www.ncbi.nlm.nih.gov/pubmed/19689168